Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 11 tags : Antibody save search
I-Mab’s Antibody for Severe COVID-19 Looks Good in Interim Analysis
Published: 2021-08-11 (Crawled : 18:00) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: -6.04%
H: 0.27%
C: -2.71%
covid antibody covid-19
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19First-in-human study evaluating recombinant hyperimmunes
Published: 2021-08-11 (Crawled : 15:00) - biospace.com/
GRFS | $6.465 2.62% 1.3M
|
Health Technology
|
| O: -0.14%
H: 1.09%
C: -0.55%
covid phase 1 antibody trial
I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19
Published: 2021-08-11 (Crawled : 13:00) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: -6.04%
H: 0.27%
C: -2.71%
covid phase 2 phase 2/3 positive antibody
Gainers vs Losers
| 85% | 15% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.99 139.2% 64M
|
Finance
CZOO | $8.67 73.75% 23M
|
EDBL | News | $6.47 72.07% 1.9M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
PALI | $6.59 33.67% 23M
|
Manufacturing
VNRX | $0.7989 33.15% 3.2M
|
Health Technology
BTCM | $3.51 30.0% 730K
|
Arts, Entertainment, and Recrea...
MLEC | $1.81 29.29% 2.8M
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.